Healthcare>Healthcare>Pharmaceuticals & Biotechnology>Pharmaceuticals
₹70.44
0.07 (0.10%)
High VOLATILITY
As on 10 Jul 2026
Price History
Market Cap
The total value of all a company's shares of stock. It's a quick way to gauge a company's size and value.
₹207 Cr
SMALL CAP
P/E Ratio
Price-to-Earnings ratio. It shows how much you pay for ₹1 of the company's earnings. A lower P/E might mean it's undervalued, but it varies by industry.
35.7
Industry
The specific business sector the company operates in. Useful for comparing with similar companies.
Pharmaceuticals
52-Week Range
The highest and lowest price at which the stock has traded in the last year (52 weeks). It helps show how volatile the stock is and where it is currently priced relative to its recent history.
52W Low₹36.3+94.0%
52W High₹164.02-57.1%
Current Price
₹70.44
Circuit Limits (5%)
The maximum allowed price movement (up or down) in a single trading day to prevent excessive volatility. If the stock hits these limits, trading may be temporarily halted.
Lower Circuit₹66.92
Upper Circuit₹73.96
Reference Price
₹70.44
Investment Checklist
Descending Channel on 1W — target ₹68.33
Composite score -39.05 (SELL) with 74.2% confidence
SuperTrend(10,3): Price above SuperTrend (Industry Standard (Swing/Medium-Term))
SuperTrend(7,3): Price above SuperTrend (Responsive Setting (Day Trading/Short-Term))
3-day momentum: -3.5% — strong downward pressure
Technical Analysis
Technical Analysis
Analysis from 2026-07-11
Confidence
74%
Trend
NEUTRAL
NEUTRAL
Mixed MA signals — sideways/transition
EMA20
70.54
EMA50
66.51
EMA200
85.29
Price Action
MIXED
NEUTRAL
Higher Highs3
Higher Lows4
Lower Highs6
Lower Lows5
Support & Resistance Levels
Resistance (Above)
₹71.00
₹71.90
₹79.69
₹82.44
₹93.51
Support (Below)
₹69.93
₹68.11
₹66.45
₹58.35
₹57.25
Volume Analysis
TrendSTABLE
Change+1.90%
Unusual VolumeNo
Stop Loss Levels
Fixed Risk
1% Risk₹69.74
3% Risk₹68.33
5% Risk₹66.92
7% Risk (Custom)
₹65.51Technical Levels
1x ATR (Volatility)₹66.25
2x ATR (Swing)₹62.06
3x ATR (Trend)₹57.87
Immediate Support₹69.93
Moving Averages
EMA 50 (Trend)₹66.51
Financials
Financial Analysis
| Metric | Mar '25 | Jun '25 | Sep '25 | Dec '25 |
|---|---|---|---|---|
| Revenue | ₹22.9 Cr | ₹25.5 Cr | ₹23.5 Cr | ₹16.6 Cr |
| Net Profit | ₹-1.5 Cr | ₹9.6 Cr | ₹8 Cr | ₹5.5 Cr |
| EPS | — | ₹3.25 | ₹2.71 | ₹1.87 |
| Operating Profit | ₹-81,23,000 | ₹10.3 Cr | ₹8.7 Cr | ₹6.1 Cr |
ROE
-10.16%
ROCE
-8.46%
Debt/Equity
0.08
Current Ratio
1.48
OPM
36.54%
NPM
33.19%
Peer Comparison
PharmaceuticalsPeer Comparison
Symbol | Name | Price | Change | P/E Ratio | Market Cap |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹1,935.50 | -0.17% | 40.2 | ₹4.64L Cr large Cap | |
| Divi's Laboratories Limited | ₹6,836.00 | +0.34% | 70.7 | ₹1.81L Cr large Cap | |
| Torrent Pharmaceuticals Limited | ₹4,901.50 | +0.07% | 77.6 | ₹1.66L Cr large Cap | |
| Cipla Limited | ₹1,439.40 | -0.13% | 30.1 | ₹1.16L Cr large Cap | |
| Zydus Lifesciences Limited | ₹1,150.80 | -0.71% | 22.8 | ₹1.16L Cr large Cap | |
| Lupin Limited | ₹2,496.30 | -0.28% | 21.3 | ₹1.14L Cr mid Cap | |
| Mankind Pharma Limited | ₹2,525.10 | -0.27% | 54.1 | ₹1.04L Cr mid Cap | |
| Dr. Reddy's Laboratories Limited | ₹1,244.30 | -1.99% | 25.1 | ₹1.04L Cr large Cap | |
| Aurobindo Pharma Limited | ₹1,564.70 | -1.43% | 25.7 | ₹90.88K Cr mid Cap | |
| Laurus Labs Limited | ₹1,537.80 | +2.02% | 93.4 | ₹83.02K Cr mid Cap | |
| Brooks Laboratories Limited | ₹70.44 | -0.10% | 35.7 | ₹207 Cr small Cap |
Corporate Information
Large Deals
View AllBulk, Block and Short deals reported for this stock.
Loading Deals...
Corporate Actions
Recent actions
| Ex Date | Purpose | Type |
|---|---|---|
| 12 Sept 2024 | Annual General Meeting | AGM |
| 14 Sept 2023 | Annual General Meeting | AGM |
| 28 Jul 2023 | Rights 1:16 @ Premium Rs 65/- | RIGHTS_ISSUE |
| 22 Sept 2022 | Annual General Meeting | AGM |
| 21 Sept 2021 | Annual General Meeting | AGM |
Announcements
Latest updates
Board Meetings
Upcoming and past meetings
Corporate Events
Upcoming results & meetings
No upcoming events found
We couldn't find any scheduled corporate actions for this symbol at the moment.
Latest News
News for BROOKS
View All
positive
ET Markets - Stocks 60d ago
Unique Picks: 6 stocks held by only one MF scheme in April, falling up to 40% in CY26
An analysis of mutual fund portfolios revealed 29 stocks held exclusively by single schemes, with most underperforming in CY26. However, Satin Creditcare Network, Rossell Techsys, and Amanta Healthcare bucked the trend, delivering strong returns. Brooks Laboratories and EFC (I) were among those experiencing significant declines.
ABSLPSEALPHAALPHAETFAMANTAAONEGOLDAONELIQUIDAONENIFTYAONETOTALAUTOBEESAUTOIETFAXISBPSETFBANK10ADDBANKADDBANKBETFBANKETFBANKPSUBBETF0432BBNPNBETFBBNPPGOLDBFSIBNKETFAXISBROOKSCHEMICALCHOICEGOLDCOMMOIETFCONSUMAXISDEFENCEDIVIDENDEBANKNIFTYEBBETF0430EBBETF0431EBBETF0433ECAPINSUREEFCILEGOLDELIQUIDELM250ENERGYENIFTYEQUAL200EQUAL50EQUAL50ADDESENSEXESGESILVERFINIETFFLEXIADDFMCGIETFGILT10BETAGILT5BETAGOLD1GOLD360GOLDADDGOLDAXISGOLDBETAGOLDBNDGOLDETFGROWWCAPMGROWWCHEMGROWWDEFNCGROWWEVGROWWGOLDGROWWHOSPIGROWWLIQIDGROWWLOVOLGROWWMC150GROWWMETALGROWWMOM50GROWWN200GROWWNETGROWWNIFTYGROWWNXT50GROWWPOWERGROWWPSEGROWWPSUBKGROWWRAILGROWWRLTYGROWWSC250GROWWSLVRGSEC10IETFGSEC10YEARHCGHCG-REHDFCGOLDHDFCGROWTHHDFCLOWVOLHDFCMID150HDFCMOMENTHDFCNEXT50HDFCNIF100HDFCNIFITHDFCPSUBKHDFCPVTBANHDFCQUALHDFCSILVERHDFCSML250HDFCVALUEHEALTHADDHEALTHAXISHEALTHCAREHEALTHIETFHSBCGOLDICICIB22INFRAIETFINTERNETITADDITAXISITBEESITBETAITETFITIETFLICNETFSENLICNMID100LIQGRWBEESLIQUIDLIQUID1LIQUIDPLUSLIQUIDSBILIQUIDSHRILOWVOLMAFANGMAHKTECHMAKEINDIAMANUFGBEESMASPTOP50METALMETALIETFMID150MIDCAPADDMIDCAPBETAMIDCAPETFMIDCAPIETFMIDQ50ADDMNCMOALPHA50MOBANK10MOCAPITALMODEFENCEMOENERGYMOGOLDMOGSECMOHEALTHMOINFRAMOIPOMOLOWVOLMOM100MOM30IETFMOM50MOMENTUMMOMENTUM30MOMENTUM50MOMGFMOMIDMTMMOMNCMOMOMENTUMMON100MON50EQUALMONEXT50MONIFTY100MONIFTY500MONQ50MOPSEMOQUALITYMOREALTYMOSERVICEMOSILVERMOSMALL250MOTOURMOVALUEMSCIADDMSCIINDIAMULTICAPNEXT30ADDNEXT50NEXT50ADDNEXT50BETANEXT50ETFNEXT50IETFNIDANNIFTY100EWNIFTYADDNIFTYAXISNIFTYBETFNIFTYETFNIFTYQLITYOILIETFPHARMABEESPSUBANKADDPSUBNKIETFPVTBANKADDQUALITY30ROSSELLINDROSSTECHSATINSBIBPBSBIETFCONSBIETFITSBIETFPBSBIETFQLTYSBILIQETFSBINEQWETFSBINMID150SBISILVERSELECTIPOSENSEXAXISSENSEXETFSETF10GILTSILVERSILVER1SILVER360SILVERADDSILVERAGSILVERAXISSILVERBEESSILVERBETASILVERBNDSILVERIETFSMALL250SMALLADDSNXT30BEESTATAGOLDTATSILVTECHTNIDETFTOP10ADDTOP20TWCGOLDETFUNIONGOLDVAL30IETFVALUEVALUEAXISCapital GoodsFast Moving Consumer Goods
neutral
Moneycontrol NaNd ago
Why the Brooks Steriscience–OneSource deal was called off
OneSource Specialty Pharma said its board decided not to proceed 'in its current form' as it was not in the best interest of stakeholders. Brooks Steriscience echoed a similar stance
BROOKSCURRENTONESOURCEConstructionHealthcare